Company Filing History:
Years Active: 2022-2025
Title: Marco Herling: Innovator in T-Cell Prolymphocytic Leukaemia Treatment
Introduction
Marco Herling is a notable inventor based in Cologne, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of T-cell prolymphocytic leukaemia. With a total of 3 patents to his name, Herling's work is recognized for its potential impact on patient care.
Latest Patents
Herling's latest patents include innovative treatments involving tinostamustine. One of his patents describes the use of tinostamustine or a pharmaceutically acceptable salt thereof for the treatment of T-cell prolymphocytic leukaemia (T-PLL) in patients who require such intervention. This therapy aims to provide a new avenue for managing this challenging condition.
Career Highlights
Throughout his career, Marco Herling has worked with reputable companies such as Purdue Pharma L.P. and Euro-Celtique S.A. His experience in these organizations has contributed to his expertise in pharmaceutical development and innovation.
Collaborations
Herling has collaborated with various professionals in the field, including his coworker Thomas Jorg Mehrling. These partnerships have likely enhanced the quality and scope of his research and inventions.
Conclusion
Marco Herling's contributions to the treatment of T-cell prolymphocytic leukaemia through his patents and collaborations highlight his role as an influential inventor in the medical field. His work continues to pave the way for advancements in patient care.